News
Public · Published
Aurinia Reports Q3 2026 Revenue of $83.7 Million, Raises Full-Year Guidance
Aurinia reported third-quarter 2026 revenue of $83.7 million, up 14% from a year earlier, with net income of $31.7 million. Nine-month revenue rose to $244.6 million and net income to $103.5 million. The company raised its 2026 total revenue guidance to $325 million–$330 million.
Published:
Updated:
What happened
Aurinia reported third-quarter 2026 revenue of $83.7 million, up 14% from a year earlier, with net income of $31.7 million. Nine-month revenue rose to $244.6 million and net income to $103.5 million. The company raised its 2026 total revenue guidance to $325 million–$330 million.
Confirmed
Global impact / market context
Higher revenue and profit mean Aurinia keeps more cash from each sale, which strengthens the cash available to fund research and operations. Raised guidance signals management expects stronger sales ahead, which can support investor confidence in future earnings.
Analyst inference
A drugmaker posting double-digit sales growth and lifting its full-year outlook shows steady demand for its products. Investors often compare such results with expectations for peers, and guidance changes can shift how the stock is valued relative to other pharmaceutical companies.
Analyst inference
What to watch
- Aurinia raised 2026 total revenue guidance to $325 million–$330 million and narrowed net product sales guidance to $310 million–$315 million, figures investors can compare with future quarterly results. Confirmed
- Watch whether the Phase 4 PRESERVE study of LUPKYNIS combined with belimumab enrolls and reports on schedule, since study progress could shape future prescribing and revenue. Proposed
- Track whether sales growth continues at the recent pace and whether costs stay controlled, because slower revenue or higher spending would reduce profit per sale and could undercut the raised outlook. Analyst inference
Evidence
- Original source link unavailable